likely threshold amyloid reduction reached patients actually benefit low doses despite effect plaques not hit threshold sandrock said accounting poor performance cognitive decline divergence curves gives dr. reisa sperling overall encouraged results pause sperling director center alzheimer research treatment brigham women hospital noted study arms small numbers patients making difficult draw conclusions said biological argument underpin threshold hypothesis wanted data larger trial traditional design sandrock theory holds happened ban2401 not new phenomenon year drug merck meant shut production plaques blocking enzyme called bace successful reducing amyloid fared dismally cognitive measures researchers terminated trial early second bace drug biogen eisai similar